• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.

View in: PubMed

subject areas
  • Animals
  • Antineoplastic Agents
  • Apoptosis
  • beta Catenin
  • Cell Proliferation
  • Cell Survival
  • Drug Resistance, Neoplasm
  • Enzyme Activators
  • Fingolimod Hydrochloride
  • Fusion Proteins, bcr-abl
  • Hematopoietic Stem Cells
  • Humans
  • Janus Kinase 2
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Mice
  • Mice, Transgenic
  • Neoplastic Stem Cells
  • Propylene Glycols
  • Protein Kinase Inhibitors
  • Protein Phosphatase 2
  • Sphingosine
  • Wnt Signaling Pathway
  • Xenograft Model Antitumor Assays

authors with profiles
  • Besim Ogretmen